Mimedx Group Inc (MDXG) 9.34 $MDXG Technical Ro
Post# of 273254
Posted On: 09/23/2016 5:16:49 AM
Mimedx Group Inc (MDXG) 9.34 $MDXG
Technical Roundup on Healthcare Stocks -- ResMed, MiMedx, Varian Medical Systems, and Accuray
PR Newswire - Fri Sep 16, 6:55AM CDT
The Medical Appliances and Equipment space was the third largest of the selected industries in 2015 with the Americas being its biggest geographical market, Europe as its second, and Asia as the third. The industry belongs to the Healthcare sector, which was up 1.5% as of midday Thursday. This morning, Stock-Callers.com reviews the recent performances of the following equities: ResMed Inc. (NYSE: RMD), MiMedx Group Inc. (NASDAQ: MDXG), Varian Medical Systems Inc. (NYSE: VAR), and Accuray Inc. (NASDAQ: ARAY). Sign up today and download for free the research reports for the stocks covered today at:
VAR: 98.50 (+0.73), RMD: 63.98 (+0.18), ARAY: 5.84 (+0.04), MDXG: 9.34 (+0.20)
MiMedx Urges FDA To Reconsider Draft Guidances During Hearing
PR Newswire - Thu Sep 15, 7:45AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company urged the Food and Drug Administration ("FDA"
to reconsider its Draft Guidances on Minimal Manipulation and Homologous Use of Human Cells, Tissues, and Cellular and Tissue Based Products (HCT/Ps) during hearings conducted on September 12 and 13, 2016.
MDXG: 9.34 (+0.20)
Scientific Study Confirms How MiMedx dHACM Allografts Effectively Promote Wound Repair
PR Newswire - Mon Sep 12, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the most recent peer-reviewed scientific study of the MiMedx dehydrated human amnion/chorion membrane ("dHACM" allografts has been electronically published in the journal Advances in Wound Care. The electronic publication of the paper, "Identification of ECM Components and Biological Factors in Micronized Dehydrated Human Amnion/Chorion Membrane," can be found athttp://online.liebertpub.com/doi/abs/10.1089/wound.2016.0699.
MDXG: 9.34 (+0.20)
MiMedx Reaffirms Q3 and Full Year 2016 Guidance
PR Newswire - Tue Sep 06, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the Company's reiteration of its previous guidance for the third quarter and full year 2016, and the results of the Company's Share Repurchase Program.
MDXG: 9.34 (+0.20)
MiMedx Announces Nationwide Launch of AmnioFill(TM)
PR Newswire - Thu Sep 01, 3:13PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its plans for the nationwide launch of AmnioFill(TM), the first product in the MiMedx placental collagen matrix product family to be commercially launched.
MDXG: 9.34 (+0.20)
MiMedx Provides Update On Key Clinical Trials
PR Newswire - Tue Aug 30, 5:10PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided an update today on the status of key clinical trials.
MDXG: 9.34 (+0.20)
MiMedx To Attend The Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 11:21AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will attend the Morgan Stanley Global Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate in one-on-one and small group meetings on Wednesday, September 14, 2016, at the Grand Hyatt New York.
MDXG: 9.34 (+0.20)
MiMedx Awarded Six New U.S. Patents with Five Awarded for its Amniotic Membrane Allografts and One Awarded for its CollaFix(TM) Technology
PR Newswire - Mon Aug 29, 10:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today an update to its intellectual property portfolio.
MDXG: 9.34 (+0.20)
MiMedx Amniotic Allografts Are Terminally Sterilized To Enhance Safety Related To Microbiological And Viral Transmission
PR Newswire - Mon Aug 22, 10:08AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that in light of the media attention and in the wake of concerns related to the Zika virus, the Company is reiterating its long standing processing safety standards for the terminal sterilization of MiMedx amniotic allografts. The MiMedx flagship amniotic allografts have always been terminally sterilized, and the Company's proprietary PURION® Process has continually used terminal sterilization as an essential part of the process. In anticipation of questions related to the Zika virus, MiMedx is reconfirming the rigorous product safety methods and practices followed by the Company in the processing of its amniotic allografts as well as restating its precise standards for screening of placenta donors.
MDXG: 9.34 (+0.20)
MiMedx announces ruling from PTAB on its embossment patent
PR Newswire - Thu Aug 11, 1:51PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today a ruling has been rendered from the Patent Trial and Appeal Board ("PTAB" of the United States Patent and Trademark Office with regard to MiMedx's United States Patent No. 8,597,687 related to the embossment of tissues. This embossment is a method for the clinician to determine which side is "up." This patent is not related to the EpiFix® or AmnioFix® patents, other than for the embossment.
MDXG: 9.34 (+0.20)
MiMedx to Present at the 36th Annual Canaccord|Genuity Growth Conference
PR Newswire - Wed Aug 03, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will present at the 36th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP & Chief Commercialization Officer, are scheduled to present on Thursday, August 11, 2016 at 11:30 a.m. eastern time, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 9.34 (+0.20)
How These Healthcare Stocks are Performing? -- Neovasc, MiMedx, InspireMD, and Amedica
PR Newswire - Wed Aug 03, 7:30AM CDT
The Medical Appliances and Equipment space remains a strong industry which is expected to continue growing given the high need and demand for health care and related instruments. Stock-Callers.com turns investors' attention to the following stocks in review: Neovasc Inc. (NASDAQ: NVCN), MiMedx Group Inc. (NASDAQ: MDXG), InspireMD Inc. (NYSEMKT: NSPR), and Amedica Corp. (NASDAQ: AMDA). Register now and get full and free access to our downloadable research reports on these stocks at: http://stock-callers.com/registration
NSPR: 0.10 (-0.01), MDXG: 9.34 (+0.20), NVCN: 0.54 (unch), AMDA: 0.96 (+0.03)
MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims
PR Newswire - Tue Jun 21, 11:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company has agreed to terms of settlement with each of Medline Industries, Inc. ("Medline" and Liventa Bioscience, Inc. ("Liventa" for false advertising claims asserted against each of them by MiMedx.
MDXG: 9.34 (+0.20)
Independent Clinical Case Series Demonstrates MiMedx dHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage
PR Newswire - Wed Jun 01, 4:43PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the most recent peer-reviewed independent clinical case series of MiMedx EpiFix® allografts has been published. The paper, "Bone and Tendon Coverage via Dehydrated Human Amniotic/Chorionic Membrane and Split-Thickness Skin Grafting," was electronically published in the Journal of Reconstructive Microsurgery.
MDXG: 9.34 (+0.20)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company" (NASDAQ: OSIR) concerning possible violations of federal securities laws.
OSIR: 4.89 (unch), MDXG: 9.34 (+0.20)
Technical Roundup on Healthcare Stocks -- ResMed, MiMedx, Varian Medical Systems, and Accuray
PR Newswire - Fri Sep 16, 6:55AM CDT
The Medical Appliances and Equipment space was the third largest of the selected industries in 2015 with the Americas being its biggest geographical market, Europe as its second, and Asia as the third. The industry belongs to the Healthcare sector, which was up 1.5% as of midday Thursday. This morning, Stock-Callers.com reviews the recent performances of the following equities: ResMed Inc. (NYSE: RMD), MiMedx Group Inc. (NASDAQ: MDXG), Varian Medical Systems Inc. (NYSE: VAR), and Accuray Inc. (NASDAQ: ARAY). Sign up today and download for free the research reports for the stocks covered today at:
VAR: 98.50 (+0.73), RMD: 63.98 (+0.18), ARAY: 5.84 (+0.04), MDXG: 9.34 (+0.20)
MiMedx Urges FDA To Reconsider Draft Guidances During Hearing
PR Newswire - Thu Sep 15, 7:45AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company urged the Food and Drug Administration ("FDA"
to reconsider its Draft Guidances on Minimal Manipulation and Homologous Use of Human Cells, Tissues, and Cellular and Tissue Based Products (HCT/Ps) during hearings conducted on September 12 and 13, 2016. MDXG: 9.34 (+0.20)
Scientific Study Confirms How MiMedx dHACM Allografts Effectively Promote Wound Repair
PR Newswire - Mon Sep 12, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the most recent peer-reviewed scientific study of the MiMedx dehydrated human amnion/chorion membrane ("dHACM"
allografts has been electronically published in the journal Advances in Wound Care. The electronic publication of the paper, "Identification of ECM Components and Biological Factors in Micronized Dehydrated Human Amnion/Chorion Membrane," can be found athttp://online.liebertpub.com/doi/abs/10.1089/wound.2016.0699. MDXG: 9.34 (+0.20)
MiMedx Reaffirms Q3 and Full Year 2016 Guidance
PR Newswire - Tue Sep 06, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the Company's reiteration of its previous guidance for the third quarter and full year 2016, and the results of the Company's Share Repurchase Program.
MDXG: 9.34 (+0.20)
MiMedx Announces Nationwide Launch of AmnioFill(TM)
PR Newswire - Thu Sep 01, 3:13PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its plans for the nationwide launch of AmnioFill(TM), the first product in the MiMedx placental collagen matrix product family to be commercially launched.
MDXG: 9.34 (+0.20)
MiMedx Provides Update On Key Clinical Trials
PR Newswire - Tue Aug 30, 5:10PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided an update today on the status of key clinical trials.
MDXG: 9.34 (+0.20)
MiMedx To Attend The Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 11:21AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will attend the Morgan Stanley Global Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate in one-on-one and small group meetings on Wednesday, September 14, 2016, at the Grand Hyatt New York.
MDXG: 9.34 (+0.20)
MiMedx Awarded Six New U.S. Patents with Five Awarded for its Amniotic Membrane Allografts and One Awarded for its CollaFix(TM) Technology
PR Newswire - Mon Aug 29, 10:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today an update to its intellectual property portfolio.
MDXG: 9.34 (+0.20)
MiMedx Amniotic Allografts Are Terminally Sterilized To Enhance Safety Related To Microbiological And Viral Transmission
PR Newswire - Mon Aug 22, 10:08AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that in light of the media attention and in the wake of concerns related to the Zika virus, the Company is reiterating its long standing processing safety standards for the terminal sterilization of MiMedx amniotic allografts. The MiMedx flagship amniotic allografts have always been terminally sterilized, and the Company's proprietary PURION® Process has continually used terminal sterilization as an essential part of the process. In anticipation of questions related to the Zika virus, MiMedx is reconfirming the rigorous product safety methods and practices followed by the Company in the processing of its amniotic allografts as well as restating its precise standards for screening of placenta donors.
MDXG: 9.34 (+0.20)
MiMedx announces ruling from PTAB on its embossment patent
PR Newswire - Thu Aug 11, 1:51PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today a ruling has been rendered from the Patent Trial and Appeal Board ("PTAB"
of the United States Patent and Trademark Office with regard to MiMedx's United States Patent No. 8,597,687 related to the embossment of tissues. This embossment is a method for the clinician to determine which side is "up." This patent is not related to the EpiFix® or AmnioFix® patents, other than for the embossment. MDXG: 9.34 (+0.20)
MiMedx to Present at the 36th Annual Canaccord|Genuity Growth Conference
PR Newswire - Wed Aug 03, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will present at the 36th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP & Chief Commercialization Officer, are scheduled to present on Thursday, August 11, 2016 at 11:30 a.m. eastern time, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 9.34 (+0.20)
How These Healthcare Stocks are Performing? -- Neovasc, MiMedx, InspireMD, and Amedica
PR Newswire - Wed Aug 03, 7:30AM CDT
The Medical Appliances and Equipment space remains a strong industry which is expected to continue growing given the high need and demand for health care and related instruments. Stock-Callers.com turns investors' attention to the following stocks in review: Neovasc Inc. (NASDAQ: NVCN), MiMedx Group Inc. (NASDAQ: MDXG), InspireMD Inc. (NYSEMKT: NSPR), and Amedica Corp. (NASDAQ: AMDA). Register now and get full and free access to our downloadable research reports on these stocks at: http://stock-callers.com/registration
NSPR: 0.10 (-0.01), MDXG: 9.34 (+0.20), NVCN: 0.54 (unch), AMDA: 0.96 (+0.03)
MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims
PR Newswire - Tue Jun 21, 11:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company has agreed to terms of settlement with each of Medline Industries, Inc. ("Medline"
and Liventa Bioscience, Inc. ("Liventa" for false advertising claims asserted against each of them by MiMedx. MDXG: 9.34 (+0.20)
Independent Clinical Case Series Demonstrates MiMedx dHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage
PR Newswire - Wed Jun 01, 4:43PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the most recent peer-reviewed independent clinical case series of MiMedx EpiFix® allografts has been published. The paper, "Bone and Tendon Coverage via Dehydrated Human Amniotic/Chorionic Membrane and Split-Thickness Skin Grafting," was electronically published in the Journal of Reconstructive Microsurgery.
MDXG: 9.34 (+0.20)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company"
(NASDAQ: OSIR) concerning possible violations of federal securities laws. OSIR: 4.89 (unch), MDXG: 9.34 (+0.20)
(0)
(0)Scroll down for more posts ▼